Silverarc Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Silverarc Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38M	Sell	390,000 -264,746	-40%	-$23.1M	3.95%	6
2026 Q1	$54.9M	Sell	654,746 -95,390	-13%	-$5.52M	5.61%	3
2025 Q4	$30.9M	Buy	750,136 +75,170	+11%	+$2.91M	4.29%	7
2025 Q3	$26.6M	Buy	674,966 +579,160	+605%	+$14.8M	3.58%	8
2025 Q2	$1.78M	Sell	95,806 -94,528	-50%	-$1.77M	0.33%	47
2025 Q1	$3.45M	Buy	+190,334	New	+$4.19M	0.71%	35

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Silverarc Capital Management's DNTH Position: Q2 2026 in Review

Silverarc Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 40% in Q2 2026, selling an estimated $23.1M and leaving 390,000 shares worth $38M. The position accounts for 3.95% of the portfolio, ranked #6.

Silverarc Capital Management first reported a position in DNTH in Q1 2025 and has held it in 6 quarters since. The position peaked at $54.9M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Silverarc Capital Management held 390,000 shares of Dianthus Therapeutics worth $38M as of Q2 2026.
Silverarc Capital Management sold 264,746 Dianthus Therapeutics shares in Q2 2026, an estimated $23.1M.
Dianthus Therapeutics made up 3.95% of Silverarc Capital Management's portfolio in Q2 2026, its #6 holding.
Silverarc Capital Management first reported a position in Dianthus Therapeutics in Q1 2025 and has held it in 6 quarters since.
Silverarc Capital Management's Dianthus Therapeutics position peaked at $54.9M in Q1 2026.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.